Clinical trial NCT02269241: Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
Official title: A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Contraception
Keywords: contraception
hormonal oral contraceptive agents
hormonal oral contraceptive
oral contraceptive
drospirenone
LF111
birth control
Lead sponsor: Insud Pharma
Sponsor class: INDUSTRY
Collaborators: name: Chemo France
First posted: 2014-10-21
Enrollment: 1552
Sex: FEMALE
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.

Detailed description: This trial is a prospective, multicenter, open-label, non-controlled trial in female subjects, including adolescents between the ages of 15+(inclusive) who present to the clinic seeking contraception, who are postmenarcheal and premenopausal.

At screening, informed consent will be obtained and the screening procedures will be performed. After confirmation of the subject's eligibility, the subject will be provided with the investigational product and trained in the use of an electronic diary. Afterwards, the subjects will attend visit the clinical site on Day 20±2 of the 1st, 3rd, 6th and 9th cycles and on Day 29+2 of the 13th cycle. The last clinical site visit will occur 10-14 days after the 13th cycle visit.

The trial will include women who have never used hormonal contraceptives before consent (naïve users), women who have not used hormonal contraceptives in the past three months before consent or who have used hormonal contraceptives in the past but have a contraceptive-free time of less than three months before consent (previous users) as well as women directly switching from another hormonal method (switchers). Women who have used hormonal contraceptives in the past but have a contraceptive-free time of less than three months before consent are allowed to be included into the trial if they had at least one complete menstrual cycle before enrollment.

A population pharmacokinetic (PK) analysis planned in the whole subject population, will obtain sparse blood samples to determine plasma concentrations. In total, four blood samples will be collected: two samples each will be collected during the 1st cycle and during the 6th cycle of treatment.

Adverse events and safety information will be collected throughout the study.

Eligibility criteria: Inclusion Criteria:

1. Sexually active, postmenarcheal and premenopausal female subjects at risk of pregnancy including breastfeeding women with no upper age limit.
2. Female subjects at risk of pregnancy, between the ages of 15 and 17 (inclusive) provided that

   * Applicable national, state and local laws allow subjects in this age group to consent/assent to receive contraceptive services, and
   * All applicable laws and regulations regarding the informed consent/assent of the subjects to participate in clinical trials are observed.
3. Regular cycles during the last six months before consent/assent when not using hormonal contraception.
4. At least three complete menstrual cycles after delivery (only applicable for women who were pregnant within the last six months and for non-breastfeeding women). Breastfeeding women can be included six weeks after delivery irrespective of menstrual cycles post-delivery.
5. At screening, maximum systolic blood pressure (median value of three values) ≤ 159 mm Hg and diastolic blood pressure (median value of three values) ≤ 99 mm Hg.
6. Be able and willing to provide written informed consent or assent if the subject is adolescent, prior to undergoing any trial-related procedure.
7. Willing to use trial contraception for thirteen 28-day cycles.
8. Be willing to have intercourse each cycle of trial without the need to use back-up contraceptive.
9. Be willing to state that, to her best knowledge, her male sexual partner(s):

   * Has not had a vasectomy or been previously diagnosed as infertile.
   * Has not been previously diagnosed or suspected of human immunodeficiency virus (HIV) unless he has subsequently had a negative HIV test.
   * Has not been known to have engaged in homosexual intercourse in the past five years unless he has had negative HIV test results since then.
   * Has not shared injection drug needles in the past unless he has had a negative HIV test at least six weeks since last use.
10. Agree not to participate in any other clinical trials during the course of this trial.

Exclusion Criteria:

1. Pregnant.
2. Subject is known to or suspected of not being able to comply with the trial protocol, the use of the trial medication or the use of the trial diary.
3. History of infertility.
4. Abnormal finding on pelvic, breast or ultrasound examination that in the investigator's opinion contraindicates participation in the trial.
5. Unexplained amenorrhea.
6. Known polycystic ovary syndrome.
7. Women ≥21 years of age with a Papanicolaou (pap) smear reading LGSIL or higher at screening (or six months prior to screening date). Human papilloma virus (HPV) testing in subjects with atypical squamous cells of undetermined significance (ASC-US) can be used as an adjunctive test.

   * Subjects with ASC-US can be included if they are negative for high-risk HPV strains.
   * Subjects \<21 years of age do not require a pap smear.
8. Known contraindication or hypersensitivity to ingredients or excipients of the IMP (Investigational Medicinal Product), including:

   1. Renal insufficiency
   2. Hepatic dysfunction
   3. Adrenal insufficiency
   4. Current or history of venous thrombophlebitis or thromboembolic disorders (venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism)
   5. Current or history of cerebral-vascular or coronary-artery disease
   6. Valvular heart disease with thrombogenic complications
   7. Diabetes with vascular involvement
   8. Headaches with focal neurological symptoms
   9. Major surgery with prolonged immobilization
   10. Known or suspected carcinoma of the breast
   11. Known or suspected sex-steroid sensitive malignancies
   12. Undiagnosed abnormal genital bleeding
   13. Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use
   14. Liver tumor (benign or malignant) or active clinically significant liver disease.
9. Uncontrolled thyroid disorder (i.e., on stable dose of thyroid replacement for less than two months).
10. Uncontrolled concomitant diseases (i.e., not on a stable treatment dose for at least two months).
11. Evidence or history of alcohol, medication or drug abuse (within the last 12 months prior to consent/assent).
12. Known inherited or acquired predisposition to venous thromboembolism or arterial thromboembolism (e.g., factor V Leiden, Prothrombin mutation, Antiphospholipid antibodies) or bruising within the last 12 months prior to consent/assent.
13. Known or suspected HIV and/or hepatitis infection at screening.
14. Received a dose of depot medroxyprogesterone acetate (DMPA or Depo-Provera®) during the 10 months prior to consent/assent, or received any combined injectable contraceptive (e.g., Cyclofem®) during the six months prior to consent/assent, or no spontaneous menses since last injection.
15. Long-term treatment (longer than seven consecutive days within a month prior to V1b) of any medication that might interfere with the efficacy of hormonal contraceptives.

    Prohibited medication include:
    1. Anticonvulsants (e.g. phenytoin, carbamazepine, oxcarbazepine, topiramate, felbamate, primidone)
    2. Barbiturates
    3. Rifampin
    4. Bosentan
    5. Griseofulvin
    6. St. John's wort (hypericum perforatum)
16. Administration of human chorionic gonadotropin (hCG) or intake of co-medication containing hCG within a month prior to V1b).
17. Progestin-releasing intra-uterine device (IUD) or contraceptive implant received or in place within the last two months prior to consent/assent.
18. Planned regular concomitant use of barrier contraceptive methods, spermicides, IUDs or other contraceptive measures (excepting occasional use for safety reasons, e.g., to reduce risk of infection).
19. Evidence or history of clinically significant psychiatric illness or suicide risk.
20. Participation in another trial of an investigational drug or device parallel to the current trial or less than 90 days before consent/assent, or previous participation in the current trial and dispensed trial medication.
21. Subject is a member of the investigator's or Sponsor's staff or a relative or family member thereof.
22. Any condition that, in the opinion of the investigator, may jeopardize protocol compliance or the scientific integrity of the trial.

Primary outcomes:
measure: Number of Pregnancies (Evaluable Cycles)
timeFrame: up to 13 months
Secondary outcomes:
measure: Number of Pregnancies (All)
timeFrame: up to 13 months
measure: Number of Pregnancies (Method Failures)
timeFrame: up to 13 months
measure: Pregnancy Ratio
timeFrame: up to 13 months
measure: Overall PI, PI for Method Failures
timeFrame: up to 13 months
measure: Number of Participants With Adverse Events as a Measure of Safety
timeFrame: up to to 13 months
measure: Tolerability; Vaginal Bleeding Pattern
timeFrame: up to 13 months
Other outcomes:
measure: Number of Pregnancies (by BMI and Weight)
timeFrame: up to 13 months
measure: Overall Pregnancies
timeFrame: up to 13 months
Locations:
city: Birmingham
country: United States
facility: Alabama Clinical Therapeutics
state: Alabama
city: Anaheim
country: United States
facility: Anaheim Clinical Trials, LLC
state: California
city: Costa Mesa
country: United States
facility: WCCT Global
state: California
city: San Diego
country: United States
facility: Women's Health Care Research Corp.
state: California
city: Denver
country: United States
facility: Downtown Women's Health Care
state: Colorado
city: Denver
country: United States
facility: Horizons Clinical Research Center, LLC
state: Colorado
city: Stamford
country: United States
facility: Stamford Therapeutics Consortium
state: Connecticut
city: Lake Worth
country: United States
facility: Altus Research
state: Florida
city: Miami
country: United States
facility: Miami Research Associates
state: Florida
city: North Miami
country: United States
facility: Segal Institute for Clinical Research
state: Florida
city: Saint Petersburg
country: United States
facility: Meridien Research - St. Petersburg
state: Florida
city: Tampa
country: United States
facility: Meridien Research - Tampa
state: Florida
city: West Palm Beach
country: United States
facility: Comprehensive Clinical Trials, LLC
state: Florida
city: Savannah
country: United States
facility: Fellows Research Alliance, Inc.
state: Georgia
city: Idaho Falls
country: United States
facility: Rosemark WomenCare Specialists
state: Idaho
city: Louisville
country: United States
facility: Bluegrass Clinical Research, Inc
state: Kentucky
city: Baltimore
country: United States
facility: Johns Hopkins School of Medicine
state: Maryland
city: Kalamazoo
country: United States
facility: Beyer Research
state: Michigan
city: Lawrenceville
country: United States
facility: Lawrence OBGYN Clinical Research, LLC
state: New Jersey
city: Plainsboro
country: United States
facility: The Center for Women's Health & Wellness, LLC
state: New Jersey
city: Albuquerque
country: United States
facility: Southwest Clinical Research
state: New Mexico
city: New York
country: United States
facility: NYU School of Medicine
state: New York
city: New Bern
country: United States
facility: Eastern Carolina Women's Center
state: North Carolina
city: Raleigh
country: United States
facility: Wake Research Associates
state: North Carolina
city: Winston-Salem
country: United States
facility: Hawthorne Medical Research, Inc.
state: North Carolina
city: Cincinnati
country: United States
facility: University of Cincinnati
state: Ohio
city: Columbus
country: United States
facility: Columbus Obstetricians-Gynecology, Inc./Radiant Research, Inc.
state: Ohio
city: Philadelphia
country: United States
facility: University of Pennsylvania School of Medicine
state: Pennsylvania
city: Philadelphia
country: United States
facility: Clinical Research Of Philadelphia
state: Pennsylvania
city: Bluffton
country: United States
facility: Fellows Research Alliance, Inc.
state: South Carolina
city: Corpus Christi
country: United States
facility: Advanced Research Associates
state: Texas
city: Dallas
country: United States
facility: Practice Research Organization
state: Texas
city: Houston
country: United States
facility: TMC Life Research, Inc.
state: Texas
city: Draper
country: United States
facility: Physicians' Research Options
state: Utah
city: Pleasant Grove
country: United States
facility: Physicians' Research Options
state: Utah
city: Norfolk
country: United States
facility: Eastern Virginia Medical School
state: Virginia
city: Seattle
country: United States
facility: Seattle Women's Health, Research, Gynecology
state: Washington
Study officials:
affiliation: Exeltis
name: Enrico Colli, MD
role: STUDY_DIRECTOR
References:
citation: Palacios S, Colli E, Regidor PA. Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime. BMC Womens Health. 2020 Oct 2;20(1):218. doi: 10.1186/s12905-020-01080-9.